MX2022000199A - Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo. - Google Patents

Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.

Info

Publication number
MX2022000199A
MX2022000199A MX2022000199A MX2022000199A MX2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A
Authority
MX
Mexico
Prior art keywords
pyrazolone
preparation
pyrimidine compound
use therefor
compound
Prior art date
Application number
MX2022000199A
Other languages
English (en)
Inventor
Qian Wang
Chi Zhang
Lin Zhang
Zhihui Zhang
Sijie Shu
Guangxin Xia
Hui Ge
Bingbin Zhang
Guoyong Huo
Chen Shi
Jiangsong Lou
Yu Mao
Jianxin Yu
Ying Ke
Yanjun Liu
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of MX2022000199A publication Critical patent/MX2022000199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente invención se describen un compuesto de pirazolona y pirimidina, y un método de preparación y un uso del mismo. En la presente invención se proporciona un compuesto de pirazolona y pirimidina como en la fórmula (I), teniendo dicho compuesto una mejor actividad inhibidora de la quinasa WEE1.
MX2022000199A 2019-06-28 2020-08-28 Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo. MX2022000199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910578299 2019-06-28
PCT/CN2020/112034 WO2020259724A2 (zh) 2019-06-28 2020-08-28 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Publications (1)

Publication Number Publication Date
MX2022000199A true MX2022000199A (es) 2022-09-29

Family

ID=73889014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000199A MX2022000199A (es) 2019-06-28 2020-08-28 Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.

Country Status (13)

Country Link
US (1) US20220324868A1 (es)
EP (1) EP4008719A4 (es)
JP (1) JP2022539460A (es)
KR (1) KR20230046270A (es)
CN (1) CN112142748B (es)
AU (1) AU2020304472A1 (es)
BR (1) BR112021026620A2 (es)
CA (1) CA3145348A1 (es)
CL (1) CL2021003498A1 (es)
CO (1) CO2022000751A2 (es)
IL (1) IL289395A (es)
MX (1) MX2022000199A (es)
WO (1) WO2020259724A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
WO2021231653A1 (en) * 2020-05-15 2021-11-18 Recurium Ip Holdings, Llc Mono- and combination therapies
CN114591334B (zh) * 2020-12-04 2023-10-20 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
WO2022251224A1 (en) * 2021-05-28 2022-12-01 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
EP4431511A1 (en) * 2021-11-09 2024-09-18 Hangzhou Glubio Pharmaceutical Co. Ltd. Wee1 protein kinase degradation agent and use thereof
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007499A1 (en) 2002-07-15 2004-01-22 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
EP2136635A4 (en) 2007-03-20 2011-07-27 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US20100113445A1 (en) 2007-03-20 2010-05-06 Smithkline Beecham Corporation Chemical Compounds
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
CA2750716A1 (en) 2009-02-25 2010-09-02 Msd K.K. Pyrimidopyrimidoindazole derivative
EP3368538B1 (en) * 2015-11-01 2021-09-01 The Regents of The University of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
JP6717457B2 (ja) * 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
CN111094253B (zh) * 2017-08-01 2023-08-29 里科瑞尔姆Ip控股有限责任公司 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
IL276802B2 (en) * 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones

Also Published As

Publication number Publication date
WO2020259724A3 (zh) 2021-02-18
IL289395A (en) 2022-02-01
US20220324868A1 (en) 2022-10-13
CN112142748A (zh) 2020-12-29
CA3145348A1 (en) 2020-12-30
JP2022539460A (ja) 2022-09-09
BR112021026620A2 (pt) 2022-06-07
EP4008719A2 (en) 2022-06-08
EP4008719A4 (en) 2023-03-22
AU2020304472A1 (en) 2022-03-03
KR20230046270A (ko) 2023-04-05
CN112142748B (zh) 2023-07-04
CL2021003498A1 (es) 2022-08-19
WO2020259724A2 (zh) 2020-12-30
CO2022000751A2 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
MX2022000199A (es) Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.
PH12018500343A1 (en) Heterocyclic amides as kinase inhibitors
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
EP4276095A3 (en) Processes for preparing ask1 inhibitors
WO2007027238A3 (en) Jak kinase inhibitors and their uses
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MX2017015837A (es) Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo.
EP3967694A4 (en) TRI-SUBSTITUTED PYRIMIDINE COMPOUND IN POSITIONS 2, 4, 6 USED AS ATR KINASE INHIBITOR
MX2022002831A (es) Compuestos heterociclicos.
MX2022000243A (es) Nuevos compuestos heterociclicos.
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
EP4067356A4 (en) TRI-HETEROCYCLIC COMPOUND AS A JAK INHIBITOR AND USE THEREOF
MX2019006079A (es) Derivados de oxoisoquinolina novedosos.
CO2018008253A2 (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina
MX2021015572A (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
EP3933044A4 (en) CONVENIENT ENZYME SYNTHESIS OF 3', 3'-CGAMP
AU2018375456A1 (en) Thieno(3,2-d)pyrimidine compound having inhibitory activity for protein kinase
EP3966204A4 (en) SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE AS BRUTON TYROSINE KINASE INHIBITORS
PH12020551736A1 (en) The crystalline forms of a compound
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.
WO2018096525A3 (en) Heteroaryl compounds and uses thereof